The 2026 expert consensus frames low‑dose radiotherapy (LDRT) as an emerging tumor immunomodulatory approach distinct from conventional high‑dose radiotherapy. Rather than relying on direct cytotoxic tumor cell killing, LDRT is described to act primarily through modulation of the tumor immune microenvironment. Key mechanistic effects outlined include promotion of dendritic cell antigen presentation, enhancement of T‑cell infiltration into tumor tissue, reversal of immunosuppressive features of the microenvironment, and remodeling of tumor vascular and stromal architecture. The consensus emphasizes that these biological effects create conditions more favorable for systemic immune therapies to exert anti‑tumor activity.
The consensus reviews clinical studies that evaluated LDRT in combination with systemic therapies. Reported clinical contexts with observed benefit include non‑small cell lung cancer (NSCLC), extensive‑stage small cell lung cancer (ES‑SCLC), and head and neck squamous cell carcinoma (HNSCC). In these settings, LDRT combined with immune checkpoint inhibitors, chemotherapy, or consolidated high‑dose radiotherapy was associated in clinical reports with increased objective response rates and improvements in patient survival. The abstract highlights favorable safety profiles across reported series. While these outcomes are presented as supportive evidence for wider application, the consensus also highlights the heterogeneity of study designs and the need for standardized protocols.
A principal focus of the consensus is on LDRT as a partner to other anti‑cancer modalities. The abstract states that LDRT has demonstrated synergistic anti‑tumor potential when paired with immunotherapy — notably immune checkpoint blockade — and that combinations with chemotherapy or high‑dose radiotherapy have also shown clinical benefit. The consensus frames LDRT as a modality that can potentiate immune‑mediated tumor control by improving antigen presentation and lymphocyte access, thereby increasing the likelihood of systemic therapeutic responses when combined with immune‑activating agents.
The consensus recognizes that current clinical practice lacks unified standards for several technical and planning parameters of LDRT. Specifically, patient selection, optimal combination strategies, appropriate dose fractionation, timing and sequencing relative to systemic therapies, and delineation of target volumes are areas without consensus across studies. The 2026 document systematically elaborates recommended approaches, but the PubMed abstract indicates that a common standardized framework has been proposed to promote consistent application; the abstract itself does not include granular regimen parameters. For detailed prescription recommendations and technical guidance, the full text should be consulted.
Clinical studies summarized in the consensus report generally describe favorable safety profiles for LDRT when used in combination regimens. The abstract indicates acceptable tolerability in the tumor types discussed, supporting LDRT as a feasible adjunct to systemic therapy or to higher‑dose radiotherapy. The consensus underscores the importance of monitoring and reporting adverse events in prospective studies to better define risk profiles across indications.
The stated aim of the consensus is to promote standardized application of LDRT and to provide a reference for clinical research and practice. While the abstract summarizes mechanisms and clinical contexts with supportive evidence, it acknowledges persistent gaps: the absence of uniform selection criteria, variability in combination regimens and timing, and inconsistent technical planning parameters. The consensus therefore provides systematic recommendations and encourages further prospective, controlled research to validate optimal dose schedules, sequencing strategies, and patient selection criteria across solid tumor types.
This expert consensus, titled “Expert consensus on application specifications of low‑dose radiotherapy in solid tumors (2026 edition),” was published in Zhonghua Zhong Liu Za Zhi (2026 Sep 23;48(9):1094–1107). The PubMed record lists DOI 10.3760/cma.j.cn112152-20260205-00080 and PMID 42764216. Both English and Chinese abstracts are available on PubMed, and the full text is accessible through the Chinese Medical Association Publishing House. All authors declared no conflicts of interest in the PubMed record.
Note: The PubMed abstract summarizes the consensus scope, mechanisms, clinical findings, and high‑level recommendations. Specific numeric dose‑fractionation schedules, detailed target volume delineation guidance, and step‑by‑step technical protocols are referenced as part of the full consensus document but are not reported in the abstract record reviewed here.